Cytotoxic chemotherapy or other anti-cancer agents known to be myelosuppressive; the duration of this interval must be discussed with the study chair and the study-assigned research coordinator prior to enrollment\r\n* >=  days after the last dose of cytotoxic or myelosuppressive chemotherapy ( days if prior nitrosourea)
At least  days after the last dose of myelosuppressive chemotherapy ( days if prior nitrosourea)
Patients must have received their last dose of known myelosuppressive anticancer therapy at least  days prior to enrollment or at least  days if nitrosourea
Myelosuppressive chemotherapy: at least  days after the last dose of myelosuppressive chemotherapy ( days if prior nitrosourea)
Participant has received no prior radiotherapy or chemotherapy for RMS (excluding steroids); at least  weeks must have passed since last dose of myelosuppressive chemotherapy or radiation therapy for conditions other than RMS; patients must have recovered from acute toxicity of any prior myelosuppressive chemotherapy or radiation therapy; prior biopsy, surgical resection and lymph node sampling is allowed
Myelosuppressive chemotherapy
Myelosuppressive chemotherapy, immunotherapy, or any investigational agent: ?  days (?  days if a nitrosourea) prior to screening.
Must not have received myelosuppressive chemotherapy within  days prior to study drug administration ( days if prior nitrosourea).
At least  days must have elapsed after the last dose of myelosuppressive chemotherapy; patients who have been treated with chemotherapy at time of recurrence are NOT eligible for either Stratum
Patients must have recovered from the toxic effects of prior therapy to grade  or better; patients must be at least  weeks form the last dose of standard cytotoxic chemotherapy or myelosuppressive biological therapy and at least  week from the last dose of non-myelosuppressive biologic therapy
At least  days after the last dose of myelosuppressive chemotherapy ( days if prior nitrosourea).
Therapy with myelosuppressive chemotherapy or biologic therapy <  days prior to registration unless the patient has recovered from the nadir of the previous treatment to a level that meets the inclusion eligibility criteria of this protocol
Patients must have recovered from the toxic effects of prior therapy and be at least  weeks from the last dose of standard cytotoxic chemotherapy or myelosuppressive biological therapy and at least  week from the last dose of non-myelosuppressive biologic therapy; any questions related to the definition of non-cytotoxic agents should be directed to the principal investigators; for those who have received radiation,  weeks must have elapsed before beginning vaccination
Patient must have received last dose of known myelosuppressive chemotherapy >  days prior to enrollment; >  days if nitrosurea
Patients on Strata C and D must have recovered from the toxic effects of prior therapy to grade  or better; patients must be at least  weeks form the last dose of standard cytotoxic chemotherapy or myelosuppressive biological therapy, at least  week from the last dose of non-myelosuppressive biologic therapy and at least  months from placement of bis-chloroethylnitrosourea (BCNU) wafers; any questions related to the definition of non-cytotoxic agents should be directed to the principal investigator
Myelosuppressive chemotherapy: must not have received within  days of entry onto this study ( days if prior nitrosourea drug) accompanied by hematopoietic recovery or  days of stopping non-myelosuppressive therapy as long as hematopoietic requirements are met
Cytotoxic chemotherapy or other chemotherapy known to be myelosuppressive: ? days after the last dose of cytotoxic or myelosuppressive chemotherapy ( days if prior nitrosourea).
Last dose of any myelosuppressive or biologic therapy was given at least  weeks before the start date for vorinostat on this protocol
Myelosuppressive chemotherapy: must not have received myelosuppressive chemotherapy within  weeks of entry onto this study (excluding hydroxyurea)\r\n* Cytoreduction with hydroxyurea can be initiated and continued for up to  hours prior to the start of CPX-
Therapy with myelosuppressive chemotherapy or biologic therapy <  days prior to registration; NOTE: patients who have recovered from cytopenia related to previous treatment and meet criteria of this protocol will be eligible
Myelosuppressive chemotherapy: at least  days after the last dose of myelosuppressive chemotherapy ( days if prior nitrosourea)
MDS: No previous myelosuppressive therapy; for the purpose of this protocol myelosuppressive chemotherapy will be defined as chemotherapy given with the intent of inducing a complete remission (e.g., standard +, high dose intermittent ARA-C [HIDAC], or Mylotarg)
MPD: No previous myelosuppressive therapy; for the purpose of this protocol myelosuppressive chemotherapy will be defined as chemotherapy given with the intent of inducing a complete remission (e.g., standard +, HIDAC, or Mylotarg)
Atypical CML: No previous myelosuppressive therapy; for the purpose of this protocol myelosuppressive chemotherapy will be defined as chemotherapy given with the intent of inducing a complete remission (e.g., standard +, HIDAC, or Mylotarg)
Patients must have received their last dose of known myelosuppressive anticancer therapy greater than  days prior to study enrollment or >  days if nitrosourea
Cytotoxic chemotherapy or other chemotherapy known to be myelosuppressive: ? days after the last dose of cytotoxic or myelosuppressive chemotherapy ( days if prior nitrosourea)
Anti-cancer agents not known to be myelosuppressive (eg, not associated with reduced platelet or absolute neutrophil counts): ? days after the last dose of agent
Myelosuppressive chemotherapy: Last dose was given at least  days before the start date for protocol therapy.
Planned non-myelosuppressive chemotherapy regimen
Chemotherapy: ? days from any myelosuppressive chemotherapy and abs neutrophil ct ?/mm ,  days if prior nitrosurea